KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biogen (BIIB) EBIAT (2016 - 2025)

Biogen has reported EBIAT over the past 17 years, most recently at -$48.9 million for Q4 2025.

  • Quarterly results put EBIAT at -$48.9 million for Q4 2025, down 118.34% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 20.79% YoY), and the annual figure for FY2025 was $1.3 billion, down 20.79%.
  • EBIAT for Q4 2025 was -$48.9 million at Biogen, down from $466.5 million in the prior quarter.
  • Over the last five years, EBIAT for BIIB hit a ceiling of $1.1 billion in Q3 2022 and a floor of -$68.1 million in Q3 2023.
  • Median EBIAT over the past 5 years was $399.0 million (2021), compared with a mean of $437.9 million.
  • Biggest five-year swings in EBIAT: soared 670.48% in 2024 and later plummeted 118.34% in 2025.
  • Biogen's EBIAT stood at $539.7 million in 2021, then fell by 13.82% to $465.1 million in 2022, then crashed by 46.48% to $248.9 million in 2023, then rose by 7.15% to $266.7 million in 2024, then plummeted by 118.34% to -$48.9 million in 2025.
  • The last three reported values for EBIAT were -$48.9 million (Q4 2025), $466.5 million (Q3 2025), and $634.8 million (Q2 2025) per Business Quant data.